drugset / Trial / NCT00492765

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

NCT00492765

Phase 4 Completed 380 enrolled Biogen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to find out if there is any benefit to adding Simvastatin to Interferon-beta-1a in patients with Multiple Sclerosis.

Timeline

Start
2006-02
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Simvastatin Small molecule 80 mg Oral
Background Interferon beta-1a Protein / enzyme biologic 30 ug Intramuscular

Indications